

REFERENCES

- ❖ **Abdel-Aziz F, Habib M, Mohamed MK, et al.** Hepatitis C virus infection in a community in the Nile Delta: population description and HCV prevalence. *Hepatology* (2000); 32:111–5.
- ❖ **Abdel-Wahab MF, Zakaria S, Kamel M, et al.** High seroprevalence of hepatitis C infection among risk groups in Egypt. *Am J Trop Med Hyg* (1994); 51: 563–567.
- ❖ **Ackerman Z., Paltiel O., Glikberg F., Ackerman E.:** Hepatitis C virus in various human body fluids: a systematic review. *Hepatol. Res.* 1998; 11: 26-40.
- ❖ **Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G.** Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. *Hepatology* 2001; 33:1358–1364.
- ❖ **Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, W et al.** Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. *Gastroenterology* 2004; 126:1302-1311.
- ❖ **Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, et al.** Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. *Gastroenterology. May* 2004; 126(5):1302-11.
- ❖ **Agha S, Tanaka Y, Saady N, Kurbanov F, Abo-Zeid M, El-Malky M, Khalaf M, Ohta N, Yoshizawa H, Mizokami M.** Reliability of hepatitis C virus core antigen assay for detection of viremia in HCV genotypes 1, 2, 3, and 4 infected blood donors: a collaborative study between Japan, Egypt, and Uzbekistan. *J Med Virol* 2004; 73:216-22.
- ❖ **Agnello V, Chung RT, Kaplan LM** A role for hepatitis C virus infection in type II cryoglobulinemia. *N Engl J Med* (1992) 327, 1490–1495.

References

- ❖ **Alberti A, and Benvegnu L.** Management of hepatitis C. *Journal of Hepatology* 2003; 38:S104-S118.
- ❖ **Alberti A, Boccato S, Ferrari A, et al.** Outcome of initially mild chronic hepatitis C. *Hepatology* 2001; 34:225A.
- ❖ **Alberti A, Vario A, Boccato S, et al.** Pathogenesis and incidence of hepatic steatosis in hepatitis C. 2002; *submitted*.
- ❖ **Alfaleh FZ, Hadad Q, Khuroo MS, Aljumah A, Algamedi A, Alashgar H, et al.** Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. *Liver Int* 2004; 24:568–574.
- ❖ **Alric L, Fort M, Izopet J, et al.** Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus. *Gastroenterology* 1997; 113:1675-1681.
- ❖ **Alter HJ, Seeff LB.** Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. *Semin Liver Dis* 2000; 20:17-35.
- ❖ **Alter MJ, Kuhnert WL, and Finelli L.** Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. *MMWR Recomm Rep* 2003; 52:1-13, 15; quiz CE1–4.
- ❖ **Alter MJ, Seeff LB, Bacon BR, Thomas DL, Rigsby MO, Di Bisceglie AM.** Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. *Ann Intern Med* 2004; 141:715-717.
- ❖ **Alter MJ.** Prevention of spread of hepatitis C. *HEPATOLOGY* 2002; 36(Suppl):S93-S98.
- ❖ **Alter MJ.** The detection, transmission, and outcome of hepatitis C virus infection. *Infect Agents Dis* 1993; 2:155–166.
- ❖ **(American Journal of Gastroenterology 2006)**
- ❖ **Anand BS, Currie S, Dieperink E, Bini EJ, Shen H, Ho SB, et al.** Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. *Gastroenterology* 2006; 130:1607–1616.
- ❖ **Annika Kau, Johannes Vermehren, Christoph Sarrazin.** Treatment predictors of a sustained virologic response in hepatitis B and C. *Journal of Hepatology* 49 (2008) 634–651.

References

- ❖ **Antonelli A., Ferri C., Fallahi P., Pampana A., Ferrari S.M., Goglia F., Ferrannini E., 2005.** Hepatitis C virus infection: evidence for an association with type 2 diabetes. *Diabetes Care* 28, 2548–2550.
- ❖ **Antoszewski B, Sitek A, Jedrzejczak M, Kasielska A, Kruk-Jeromin J.** Are body piercing and tattooing safe fashions? *Eur J Dermatol* 2006;16:572 -575.
- ❖ **Arafa N, El Hoseiny M, Rekacewicz C, Bakr I, El-Kafrawy S, El Daly M, Aoun S, Marzouk D, Mohamed MK, Fontanet A.** Changing pattern of hepatitis C virus spread in rural areas of Egypt. *J Hepatol* 2005; 43:418–24.
- ❖ **Arena U, Vizzutti F, Corti G, Ambu S, Stasi C, Bresci S, et al.** Acute viral hepatitis increases liver stiffness values measured by transient elastography. *HEPATOLOGY* 2008;47:380-384.
- ❖ **Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ.** The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. *Ann Intern Med* 2006; 144:705-714.
- ❖ **Ascione A, De Luca M, Tartaglione MT, et al.** Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. *Gastroenterology*. Jan 2010; 138(1):116-22.
- ❖ **Balasekaran R, Bulterys M, Jamal MM, Quinn PG, Johnston DE, Skipper B, et al.** A case-control study of risk factors for sporadic hepatitis C virus infection in the southwestern United States. *Am J Gastroenterol* 1999; 94:1341-1346.
- ❖ **Bassett SE, Guerra B, Brasky K, et al.** Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. *Hepatology* 2001; 33: 1479–87.
- ❖ **Bassily S, Hyam KC, El Masery.** Hepatitis C virus and hepatosplenic schistosomiasis. *Scand J Infect Dis* 1992; 24:687:688.
- ❖ **Batts KP, Ludwig J.** Chronic hepatitis. An update on terminology and reporting. *Am J Surg Pathol* 1995; 19:1409-1417.

References

- ❖ **Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J.** An inventory for measuring depression. *Arch Gen Psychiatry* 1961; 4:561-571.
- ❖ **Bedossa P, Poynard T.** An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. *HEPATOLOGY* 1996; 24:289-293.
- ❖ **Bellecave P, Sarasin-Filipowicz M, Donzé J, ennelGouttenoire J, Meylan E, Terracciano L, Tschopp J, Sarrazin C, Berg T, Moradpour D, Heim MH** 2009 Cleavage of MAVS in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system. *Hepatology* 2009; in press
- ❖ **Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al.** Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfecting patients. The Multivirc Group. *HEPATOLOGY* 1999; 30:1054-1058.
- ❖ **Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, et al.** Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. *Jama* 2008; 299:914-924.
- ❖ **Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, et al.** Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. *Hepatology* 2003; 37:600–609.
- ❖ **Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al.** Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. *Gastroenterology* 2006; 130:1086-1097.
- ❖ **Boccatto S, Pistis R, Noventa F, Guido M, Benvegna L, Alberti A.** Fibrosis progression in initially mild chronic hepatitis C. *J Viral Hepat* 2006; 13:297-302.
- ❖ **Boddi M., Abbate R., Chellini B., Giusti B., Solazzo V., Sofi F., Pratesi G., Pratesi C., Gensini G.F., Zignego A.L.,** (2007). HCV infection facilitates asymptomatic carotid atherosclerosis: preliminary report of HCV RNA localization in human carotid plaques. *Digestive and Liver Diseases* 39, 54–59.

References

- ❖ **Bonkovsky HI , and Woolley JM.** Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. *Hepatology* 1999; 29:264-270.
- ❖ **Bonkovsky HL, Naishadham D, Lambrecht RW, Chung RT, Hoefs JC, Nash SR, et al.** Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. *Gastroenterology* 2006;131: 1440–1451.
- ❖ **Boyer JL, Chang EB, Collyar DE, et al,** for the NIH Consensus Development Panel. NIH consensus statement on management of hepatitis C: 2002. *NIH Consens State Sci Statements*. Jun 10-12 2002; 19(3):1-46.
- ❖ **Brau N, Bini EJ, Currie S, Shen H, Schmidt WN, King PD, et al.** Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin. *J Viral Hepat* 2006; 13:242–249.
- ❖ **Bressler BL, Guindi M, Tomlinson G, Heathcote J.** High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. *Hepatology* 2003;38:639–644.
- ❖ **Briggs ME, Baker C, Hall R, Gaziano JM, Gagnon D, Bzowej N, et al.** Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center. *HEPATOLOGY* 2001 ; 34:1200-1205.
- ❖ **Bruguera M., Saiz J.C., Franco S., Gimenez-Barcons M., Sanchez-Tapias J.M., Fabregas S., Vega R., Camps N., Dominguez A., Sal- leras L.:** Outbreak of nosocomial hepatitis C virus infection resolved by genetic analysis of HCV RNA. *J. Clin. Microbiol.* 2002; 40: 4363-4366.
- ❖ **BruixJ, ShermanM.** *Management* of hepatocellular Carcinoma. *HEPATOLOGY*.2005; 42:1208-1236.145.
- ❖ **Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegna L, Mazzella G,et al.** Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study.*HEPATOLOGY* 2007;45:579-587.

References

- ❖ **Buti M, Sanchez-Avila F, Lurie Y, Stalgis C, Valdes A, Martell M, et al.** Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. *HEPATOLOGY* 2002; 35:930-936.
- ❖ **Cacoub P, Renou C, Rosenthal E et al. (2000)** Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. *Medicine (Baltimore)* 79, 47–56.
- ❖ **Cadranel JF, Rufat P, Degos F.** Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). *HEPATOLOGY* 2000; 32:477-481. *HEPATOLOGY*, Vol. 49, No. 4, 2009 GHANY ET AL. 1365
- ❖ **Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, et al.** Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. *Neuropsychopharmacology* 2002; 26:643-652.
- ❖ **Carlsson T, Reichard O, Norkrans G, Blackberg J, Sangfelt P, Wallmark E, et al.** Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response. *J Viral Hepat* 2005; 12:473-480.
- ❖ **Carroll ST, Riffenburgh RH, Roberts TA, Myhre EB.** Tattoos and body piercings as indicators of adolescent risk-taking behaviors. *Pediatrics* 2002; 109:1021-1027.
- ❖ **Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al.** Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. *Gastroenterology* 2005; 128:343-350.
- ❖ **Centers for Disease Control and Prevention.** Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. *MMWR Recomm Rep* 1998; 47:1-39.

References

- ❖ **Chamot E, Hirschel B, Wintsch J, Robert CF, Gabriel V, Deglon JJ, et al** .Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users. *Aids* 1990; 4:1275-1277.
- ❖ **Chen L, Borozan I, Feld J, Sun J, Tannis LL, Coltescu C, et al**.Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection.*Gastroenterology* 2005;128:1437–1444.
- ❖ **Chen M.; Yun Z.-B., Schvarcz R., Bergquist I., Berglund H.-B., Sönnnerborg A.**: Detection of hepatitis C virus RNA in the cell fraction of saliva before and after oral surgery. *J. Med. Virol.* 1995; 43: 223-226.
- ❖ **Cheruvattath R, Rosati MJ, Gautam M, Vargas HE, Rakela J, Balan V**.Pegylated interferon and ribavirin failures: is retreatment an option? *Dig Dis Sci* 2007; 52:732-736.
- ❖ **Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM**. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. *Hepatology* 2007; 46:22–31.
- ❖ **Chitsulo L, Engels D, Montresor A & Savioli L**. The global status of schistosomiasis and its control. *Acta Trop* 2000; 77: 41–51.
- ❖ **Choo Q.L, et al**. Isolation of a cDNA clone derived from a bloodborne non-A, non-B viral hepatitis genome. *Science*, 1989.244 (4902):359-62.
- ❖ **Christina Frank, Mostafa K Mohamed, G Thomas Strickland, Daniel Lavanchy, Ray R Arthur, Laurence S Magder, Taha El Khoby, Yehia Abdel-Wahab, El Said Aly Ohn, Wagida Anwar, Ismail Sallam**. 2000. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. *Lancet* 2000; 355: 887–891
- ❖ **Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al**. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. *N Engl J Med*. Jul 29 2004; 351(5):451-9.

References

- ❖ **Cody S.H., Nainan O.V., Garfein R.S., Meyers H., Bell B.P., Shapiro C.N., Meeks E.L., Pitt H., Mouzin E., Alter M.J., Margolis H.S., Vugia D.J.:** Hepatitis C virus transmission from an anaesthesiologist to a patient. *Arch. Intern. Med.* 2002; 162: 345-350.
- ❖ **Cohen, 1999;** *Management of Hepatitis C, NIH Consensus statement Online.*
- ❖ **Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly F, Trepo C.** Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. *J Viral Hepat* 2001; 8:87-95.
- ❖ **Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, et al.** Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. *Gastroenterology* 2006; 131:470–477.
- ❖ **Conry-Cantilena C, VanRaden M, Gibble J, Melpolder J, Shakil AO, Viladomiu L, et al.** Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. *N Engl J Med* 1996; 334:1691-1696.
- ❖ **Conte D, Fraquelli M, Prati D, Colucci A, Minola E.** Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of 1364 GHANY ET AL. *HEPATOLOGY*, April 2009 HCVvertical transmission in a cohort of 15,250 pregnant women.*HEPATOLOGY* 2000;31:751-755.
- ❖ **Cornberg M, Hadem J, Herrmann E, Schuppert F, Schmidt HH, Reiser M, et al.** Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized openlabel pilot study. *J Hepatol* 2006; 44:291-301.
- ❖ **Cotler SJ, Wartelle CF, Larson AM, Gretch DR, Jensen DM, Carithers RL Jr.** Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C. *J Viral Hepat* 2000;7:211-217.
- ❖ **Cox AL, Netski DM, Mosbruger T, et al.** Prospective evaluation of community-acquired acute hepatitis C. *Clin Infect Dis* 2005;40:951- 8.

References

- ❖ **Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR.** A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. **Liver Transpl.** Apr 2002; 8(4):350-5..
- ❖ **Crockett SD, Kaltenbach T, Keeffe EB.** Do we still need a liver biopsy? Are the serum fibrosis tests ready for prime time? *Clin Liver Dis* 2006; 10:513-534, viii.
- ❖ **Czaja AJ, Carpenter HA, Santrach PJ, Moore SB.** Host- and disease-specific factors affecting steatosis in chronic hepatitis C. *J Hepatol* 1998; 29:198–206.
- ❖ **Czaja AJ, Freese DK.** Diagnosis and treatment of autoimmune hepatitis. *HEPATOLOGY* 2002; 36:479-497.
- ❖ **Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, et al.** Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. *HEPATOLOGY* 2004; 40:1260-1265.
- ❖ **Dalgard O, Bjoro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, Skovlund E, et al.** Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. *Hepatology* 2008; 47:35–42.
- ❖ **Datz C., Cramp M., Haas T., Dietze O., Nitschko H., Froesner G., Muss N., Sandhofer F., Vogel W.:** The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre. *Gut* 1999; 44: 563-567.
- ❖ **Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, et al.** Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. *N Engl J Med.* Nov 30 1989; 321(22):1501-6.
- ❖ **Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J.** Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. *HEPATOLOGY* 2003; 38:645-652.

References

- ❖ **Del Rio RA, Post AB, Singer ME.** Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis combination therapy. *HEPATOLOGY* 2006;44:1598-1606.
- ❖ **Delage G., Infante-Rivard C., Chiavetta J.A., Willems B., Pi D., Fast M.:** Risk factors for acquisition of hepatitis C virus infection in blood donors: results of a case-control study. *Gastroenterology* 1999; 116: 893-899.
- ❖ **Delarocque-Astagneau E., Baffoy N., Thiers V., Simon N., de Valk H., Laperche S., Courouce A.M., Astagneau P., Buisson C., Desencios J.C.:** Outbreak of hepatitis C virus infection in a hemodialysis unit: Potential transmission by the hemodialysis machine? *Infect. Contr. Hosp. Epidem.* 2002; 23: 328-334.
- ❖ **Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ.** Classification of chronic hepatitis: diagnosis, grading and staging. *HEPATOLOGY* 1994; 19:1513-1520.
- ❖ **Deuffic-Burban S, Mohamed MK, Larouze B, Carrat F, Valleron AJ.** Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections. *J Hepatol* 2006;44:455–61
- ❖ **Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB.** Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. *J Viral Hepat* 2007; 14:107-115.
- ❖ **Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al.** Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. *N Engl J Med.* Nov 30 1989; 321(22): 1506-10.
- ❖ **Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al.** Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. *N Engl J Med* 2008; 359:2429-2441.
- ❖ **Dienstag JL.** The role of liver biopsy in chronic hepatitis C. *HEPATOLOGY* 2002; 36(Suppl):S152-S160.
- ❖ **Distante S, Bjoro K, Hellum KB, Myrvang B, Berg JP, Skaug K, et al.** Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. *Liver* 2002; 22:269–275.

References

- ❖ **Dufour DR, Talastas M, Fernandez MD, Harris B, Strader DB, Seeff LB.** Low-positive anti-hepatitis C virus enzyme immunoassay results: an important predictor of low likelihood of hepatitis C infection. *Clin Chem* 2003; 49:479-486.
- ❖ **Dusheiko G.M., Smith M., Scheuer P.J.:** Hepatitis C virus transmitted by human bite. *Lancet* 1990; 336: 503-504.
- ❖ **Egyptian Ministry of Health Annual report. 2007** Available at <http://www.mohp.gov.eg/Main.asp>. Accessed: 12 October 2008.
- ❖ **El Gaafary MM, Rekacewicz C, Abdel-Rahman AG, Allam MF, ElHosseiny M, Hamid MA, Colombani F, Sultan Y, El-Aidy S, Fontanet A, Mohamed MK.** Surveillance of acute hepatitis C in Cairo, Egypt. *J Med Virol* 2005;76:520–5.
- ❖ **El Sherbini A, Mohsen SA, Seleem Z, Ghany AA, Moneib A, Abaza AH.** Hepatitis B virus among schoolchildren in an endemic area in Egypt over a decade: impact of hepatitis B vaccine. *Am J Infect Control* 2006; 34:600–2.
- ❖ **El Katsha S, Labeeb S, Watts S, Younis A.** Informal health providers and the transmission of hepatitis C virus: pilot study in two Egyptian villages. *East Mediterr Health J* 2006; 12: 758–67.
- ❖ **El-Kady IM, Lotfy M, Badra G, El-Masry S, Waked I.** Interleukin (IL)-4, IL-10, IL-18 and IFN-gamma cytokines pattern in patients with combined hepatitis C virus and *Schistosoma mansoni* infections. *Scand J Immunol* 2005; 61: 87-91.
- ❖ **El-Khoby T, Galal N, Fenwick A, et al.** The epidemiology of schistosomiasis in Egypt: summary findings in nine governorates. *Am J Trop Med Hyg* 2000; 62: 88–99 .
- ❖ **El-Serag HB and Everhart JE.** Diabetes increases the risk of acute hepatic failure. *Gastroenterology* 2002; 122:1822-1828.
- ❖ **El-Zayadi AR, Badran HM, Barakat EM, Attia Mel-D, Shawky S, Mohamed MK, Selim O, Saeid A.** Hepatocellular carcinoma in Egypt: a single center study over a decade. *World J Gastroenterol* 2005; 11:5193–8.
- ❖ **El-Zayadi AR.** Course of schistosomiasis on Egyptian liver. *World J Gastroenterol* 2004; 10:1079–81.

References

- ❖ **Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al.** Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. *N Engl J Med* 1996; 334:77–81.
- ❖ **Esteban JI, Genesca J, Alter HJ.** Hepatitis C: molecular biology, pathogenesis, epidemiology, clinical features, and prevention. *Prog Liver Dis* 1992; 10:253–282.
- ❖ **Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, et al.** Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. *Hepatology* 2006; 44:1675–1684.
- ❖ **Everson GT.** Treatment of chronic hepatitis C in patients with decompensated cirrhosis. *Rev Gastroenterol Disord.* 2004; 4 Suppl 1:S31-8. .
- ❖ **Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P.** Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. *Aliment Pharmacol Ther.* Dec 2003; 18(11-12):1071-81.
- ❖ **Fartoux L, Chazouilleres O, Wendum D, Poupon R, Serfaty L.** Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. *Hepatology* 2005;41:82–87.
- ❖ **Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al.** Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. *Gastroenterology* 1997; 112:463-472.
- ❖ **Feray C., Gigou M., Samuel D., Paradis V., Wilber J., David M.F.,** C virus infection after liver transplantation. *Hepatology* 1994; 20: 1137-1143.
- ❖ **Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL Jr, et al.** Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. *J Hepatol* 2005; 43:425-433.
- ❖ **Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, et al.** Peginterferon Alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. *Gastroenterology* 2008.

References

- ❖ **Fischler B., Lindh G., Lindgren S., Forsgren M., von Sydow M., Sangfelt P., Alaeus A., Harland L., Enockson E., Nemeth A.:** Vertical transmission of hepatitis C virus infection. *Scand. J. Infect. Dis.* 1996; 28: 353-356.
- ❖ **Fleckenstani JF. Ismail MK, Bockhold K, et al.** South Central Liver Study Group. African American response rate to therapy for hepatitis C. *Hepatology* 1998; 28:482.
- ❖ **Fontaine H, Nalpas B, Poulet B, Carnot F, Zylberberg H, Brechot C, et al.** Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C. *Hum Pathol* 2001;32:904-909.
- ❖ **Fontana RJ, Israel J, LeClair P, Banner BF, Tortorelli K, Grace N, et al.** Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. *HEPATOLOGY* 2000; 31:730-736.
- ❖ **Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR.** The association between hepatitis C infection and survival after orthotopic liver transplantation. *Gastroenterology.* Apr 2002; 122(4):889-96.
- ❖ **Forns X, Martinez-Bauer E, Feliu A, Garcia-Retortillo M, Martin M, Gay E, Navasa M, Sanchez-Tapias JM, Bruguera M, Rodes J.** Nosocomial transmission of HCV in the liver unit of a tertiary care center. *HEPATOLOGY* 2005; 41:115-122.
- ❖ **Fracanzani AL, Conte D, Fraquelli M, Taioli E, Mattioli M, Losco A, et al.** Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. *Hepatology* 2001;33:647-651.
- ❖ **Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, El Khoby T, Abdel-Wahab Y, Aly Ohn ES, Anwar W, Sallam I.** The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. *Lancet* 2000; 355:887-91.
- ❖ **Freeman AJ, Dore GJ, Law MG, et al.** Estimating progression to cirrhosis in chronic hepatitis C virus infection. *Hepatology* 2001;34:809-816

References

- ❖ **Fried MW, Hadziyannis SJ, Shiffman M, Messinger D, Zeuzem S.** Rapid viral response is a more important predictor of sustained virological response (SVR) than genotype in patients with chronic hepatitis c virus infection. *J Hepatol* 2008; 48 (Suppl.2):5A.
- ❖ **Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçalves FL Jr, et al.** Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med.* Sep 26 2002; 347(13):975-82.
- ❖ **Gad RR Males S, El Makhzangy H, Shouman S, Hasan A, Attala M, El Hoseiny M, Zalata K, Abdel-Hamid M, Fontanet A, Mohamed MK, Esmat G.** Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C. *Liver Int.* 2008 Sep; 28(8):1112-9. Epub 2008 Apr 7
- ❖ **Garcia-Bengoechea M., Emparanza J.I., Sarriugarte A., Cortes A., Vega J.L., Gonzalez F., Arenas J.I.:** Antibodies to hepatitis C virus: a cross-sectional study in patients attending a trauma unit or admitted to hospital for elective surgery. *Eur. J. Gastroenterol. Hepatol.* 1995; 7: 237-241.
- ❖ **Gehrke SG, Stremmel W, Mathes I, Riedel HD, Bents K, Kallinowski B.** Hemochromatosis and transferrin receptor gene polymorphisms in chronic hepatitis C: impact on iron status, liver injury and HCV genotype. *J Mol Med* 2003; 81:780–787.
- ❖ **Germer JJ, Rys PN, Thorvilson JN, Persing DH.** Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test. *J Clin Microbiol* 1999; 37:2625-2630.
- ❖ **Gerotto M, Dal Pero F, Bortoletto G, Realdon S, Ferrari A, Boccato S, et al.** PKR gene expression and response to pegylated interferon plus ribavirin therapy in chronic hepatitis C. *Antivir Ther* 2004;9:763–770.
- ❖ **Ghany MG, Strader DB, Thomas DL, Seeff LB.** Diagnosis, management, and treatment of hepatitis C: an update. *Hepatology.* Apr 2009; 49(4):1335-74.

References

- ❖ **Goedert JJ, Chen BE, Preiss L, Aledort LM, Rosenberg PS.** Reconstruction of the hepatitis C virus epidemic in the US hemophilia population, 1940-1990. *Am J Epidemiol* 2007; 165:1443- 1453.
- ❖ **Goetz A.M., Ndimbie O.K., Wagener M.M., and Muder R.R.:** Prevalence of hepatitis C infection in health care workers affiliated with a liver transplant center. *Transplantation* 1995; 59: 990-994.
- ❖ **Grando-Lemaire V., Goisset P., Sorge F., Trinchet J.C., Castera L., Roulot D., Sitruk V., Beaugrand M.:** Hepatitis C virus screening in drug users in an addiction out-patient unit. *Gastroenterol. Clin. Biol.* 2002; 26: 1091-1096. H.: Increased risk of mother-to-infant transmission of hepatitis C virus by intrapartum infantile exposure to maternal blood. *J. Infect. Dis.* 2003; 187: 345-351.
- ❖ **Haddad J., Deny P., Munz-Gotheil C., Ambrosini J.C., Trinchet J.C., Pateron D., Mal F., Callard P., Beaugrand M., 1992.** Lymphocytic sialadenitis of Sjogren's syndrome associated with chronic hepatitis C virus liver disease. *Lancet* 339, 321–323.
- ❖ **Hadziyannis SJ, Sette Jr H, Morgan TR, Balan V, Diago M, Marcellin P, et al.** Peginterferon a-2a and ribavirin combination therapy in chronic hepatitis C. *Ann Intern Med* 2004;140:346–55.
- ❖ **Halim AB, Garry RF, Dash S, Gerber MA.** Effect of schistosomiasis and hepatitis on liver disease. *Am J Trop Med Hyg* 1999; 60:915–20 .
- ❖ **Harris DR, Gonin R, Alter HJ, et al.** The relationship of acute transfusion—associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. *Ann Intern Med* 2001; 134:120-124.
- ❖ **Hassan MI, Kassim SK, Ali HS, Sayed el-DA, Khalifa A.** Evaluation of nitric oxide (NO) levels in hepatitis C virus (HCV) infection: relationship to schistosomiasis and liver cirrhosis among Egyptian patients. *Dis Markers* 2002; 18: 137-142.
- ❖ **Hassan MM, Zaghloul AS, El-Serag HB, Soliman O, Patt YZ, Chappell CL, Beasley RP, Hwang LY.** The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients. *J Clin Gastroenterol* 2001;33:123–6

References

- ❖ **Hayashi N, Kasahara A.** Interferon for decreasing the incidence of hepatocellular carcinoma in patients with chronic hepatitis C. *Oncology*. 2002; 62 Suppl 1:87-93.
- ❖ **Healey C.J., Smith D.B., Walker J.L., Holmes E.C., Fleming K.A., Chapman R.W.G., Simmonds P.** Acute hepatitis C infection after sexual exposure. *Gut* 1995; 36: 148-150.
- ❖ **Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, et al.** Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. *N Engl J Med*. Dec 7 2000; 343(23):1673-80.
- ❖ **Helal TE, Danial MF, Ahmed HF.** The relationship between hepatitis C virus and schistosomiasis: histopathologic evaluation of liver biopsy specimens. *Hum Pathol* 1998; 29: 743-749.
- ❖ **Hepburn MJ, Hepburn LM, Cantu NS, Lapeer MG, Lawitz EJ.** Differences in treatment outcome for hepatitis C among ethnic groups. *Am J Med*. Aug 1 2004; 117(3):163-8.
- ❖ **Hinrichsen H., Leimenstoll G., Stegen G., Schrader H., Fölsch U.R., Schmidt W.E.** Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients. *Gut* 2002; 51: 429-433.
- ❖ **Hofer H, Osterreicher C, Jessner W, Penz M, Steindl-Munda P, Wrba F, et al.** Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C. *J Hepatol* 2004;40:1018–1022.
- ❖ **Hofmann WP, et al.** Comparison of conventional PCR with realtime PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5. *J Clin Microbiol* 2006;44:729–737.
- ❖ **Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, et al.** Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. *N Engl J Med*. Dec 18 1986; 315(25):1575-8. .

- ❖ **Hoofnagle JH.** Course and outcome of hepatitis C. *Hepatology* 2002; 36(Suppl 1):S21–9.
- ❖ **Hui CK, Monto A, Belaye T, Lau E, Wright TL.** Outcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum amino-transaminases. *Gut. Nov* 2003; 52(11):1644-8.
- ❖ **Hui JM, Kench J, Farrell GC, Lin R, Samarasinghe D, Liddle C, et al.** Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. *J Gastroenterol Hepatol* 2002; 17:873–881.
- ❖ **Hwang LY, Kramer JR, Troisi C, Bull L, Grimes CZ, Lyster R, et al.** Relationship of cosmetic procedures and drug use to hepatitis C and hepatitis B virus infections in a low-risk population. *HEPATOLOGY* 2006; 44:341-351.
- ❖ **Hwang SJ, Luo JC, Chu CW, Lai CR, Lu CL, Tsay SH, et al.** Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. *J Gastroenterol Hepatol* 2007; 52(11):1644-8
- ❖ **Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al.** Histological grading and staging of chronic hepatitis. *J Hepatol* 1995;22:696-699.
- ❖ **Ishizaka N., Ishizaka Y., Takahashi E., Tooda E., Hashimoto H., Nagai R., Yamakado M., 2002.** Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. *Lancet* 359, 133–135.
- ❖ **Izumi N, Enomoto N, Uchihara M, Murakami T, Ono K, Noguchi O, et al.** Hepatic iron contents and response to interferon-alpha in patients with chronic hepatitis C. Relationship to genotypes of hepatitis C virus. *Dig Dis Sci* 1996;41:989–994
- ❖ **Jacobson IM, Ahmed F, Russo MW, Lebovics E, Dieterich DT, Esposito SP, et al.** Interferon alfa-2b [correction of alpha-2b] and ribavirin for patients with chronic hepatitis C and normal ALT. *Am J Gastroenterol. Sep* 2004; 99(9):1700-5.
- ❖ **Jacobson IM, Brown RS Jr, Freilich B, Afdhal N, Kwo PY, Santoro J, et al.** Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. *HEPATOLOGY* 2007;46:971-981.

References

- ❖ **Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al.** Treatment of acute hepatitis C with interferon alfa-2b. *N Engl J Med.* Nov 15 2001; 345(20):1452-7.
- ❖ **Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR.** Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. *Hepatology* 2004; 39:1702–1708.
- ❖ **Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al.** Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. *HEPATOLOGY* 2006;43:954-960.1366
GHANY ET AL. HEPATOLOGY, April 2009
- ❖ **Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al.** Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. *Hepatology* 2006; 43:954–960.
- ❖ **Jessner W, Stauber R, Hackl F, Datz C, Watkins-Riedel T, Hofer H, et al.** Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection. *J Viral Hepat* 2003; 10:37–42.
- ❖ **Jonas MM.** Children with hepatitis C. *HEPATOLOGY* 2002; 36(Suppl): S173-S178.
- ❖ **Jorquera F, Monte MJ, Guerra J, Sanchez-Campos S, Merayo JA, Olcoz JL, et al.** Usefulness of combined measurement of serum bile acids and ferritin as additional prognostic markers to predict failure to reach sustained response to antiviral treatment in chronic hepatitis C. *J Gastroenterol Hepatol* 2005;20:547–554.
- ❖ **Kalantar-Zadeh K, Miller LG, Daar ES.** Diagnostic discordance for hepatitis C virus infection in hemodialysis patients. *Am J Kidney Dis* 2005; 46:290-300 .
- ❖ **Kamal S, Madwar M, Bianchi L, et al.** Clinical, virological and histopathological features: long-term follow-up in patients with chronic hepatitis C co-infected with *S. mansoni*. *Liver Int* 2000; 20: 281–289.
- ❖ **Kamal S, Nasser I.** Hepatitis C genotype 4: what we know and what we don't yet know. *Hepatology* 2008; 47: 1371–83.

References

- ❖ **Kamal SM, El Kamary SS, Shardell MD, Hashem M, Ahmed IN, Muhammadi M, et al.** Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. *HEPATOLOGY* 2007; 46:1732-1740.
- ❖ **Kamel, M.A., Ghaffar, Y.A., Wasef, M.A., Wright, M., Clark, L.C., Miller, F.D., 1992.** High HCV prevalence in Egyptian Blood donors. *Lancet*. 340(8816): p. 427.
- ❖ **Kenny-Walsh E for the Irish Hepatology Research Group.** Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. *N Eng J Med* 1999; 340:1228-1233.
- ❖ **Keyur Patel, Andrew J Muir and John G McHutchison.** Diagnosis and treatment of chronic hepatitis *BMJ* 2006; 332;1013-1017
- ❖ **Khuroo MS, Khuroo MS, Dahab ST.** Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. *Aliment Pharmacol Ther* 2004; 20:931-938.
- ❖ **Kim WR.** The burden of hepatitis C in the United States. *HEPATOLOGY* 2002; 36(Suppl):S30-S34.
- ❖ **King CL, Medhat A, Malhotra I, et al.** Cytokine control of parasite-specific anergy in human urinary schistosomiasis. IL-10 modulates lymphocyte reactivity. *J Immunol* 1996; 156: 4715–4721.
- ❖ **Kleiner DE.** The liver biopsy in chronic hepatitis C: a view from the other side of the microscope. *Semin Liver Dis* 2005; 25:52-64.
- ❖ **König V., Bauditz J., Lobeck H., Lüsebrink R., Neuhaus P., Blumhardt G., Bechstein W.O., Neuhaus R., Steffen R., Hopf U.:** Hepatitis C virus reinfection in allografts after orthotopic liver transplantation. *Hepatology* 1992; 16: 1137-1143.
- ❖ **Knobler H., Schihmanter R., Zifroni A., Fenakel G., Schattner A., 2000.** Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. *Mayo Clin. Proc.* 75, 355–359.
- ❖ **Kobayashi S, Takeda T, Enomoto M, Tamori A, Kawada N, Habu D, et al.** Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. *Liver Int* 2007; 27:186-191.

References

- ❖ **Krause G., Trepka M.J., Whisenhunt R.S., Katz D., Nainan O., Wiersma S.T., and Hopkins R.S.:** Nosocomial transmission of hepatitis C virus associated with the use of multidose saline vials. *Infect. Contr. Hosp. Epidem.* 2003; 24: 122-127.
- ❖ **Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H.** Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. *Br J Surg.* Apr 2002; 89(4):418-22.
- ❖ **Kumar R.M. and Shahul S.:** Role of breast-feeding in transmission of hepatitis C virus to infants of HCV-infected mothers. *J. Hepatol.* 1998; 29: 191-197.
- ❖ **Kuneler S. Baumann M, Schirmacher F, et al.** Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor. *B J Virol* 2001; 8:430—437.
- ❖ **Laguno M, Murillas J, Blanco JL, Martínez E, Miquel R, Sánchez-Tapias JM, et al.** Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. *AIDS.* Sep 3 2004; 18(13): F27-36. .
- ❖ **Larglu A., Zuin M., Crosignani A., Ribero M.L., Pipia C., Battezzati P.M., Binelli G., Donato F., Zanetti A.R., Podda M., Tagger A.:** Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies. *Hepatology* 2002; 36: 963-1000.
- ❖ **Lauer G.M and Walker B.D.** Hepatitis C virus infection. *N Engl J Med*, 2001. 345(1): 41-52
- ❖ **Laumann AE, Derick AJ.** Tattoos and body piercings in the United States: a national data set. *J Am Acad Dermatol* 2006; 55:413-421.
- ❖ **Lavanchy D, McMahon B.** Worldwide prevalence and prevention of hepatitis C. In: *Liang TJ, Hoofnagle JH, eds. Hepatitis C. San Diego, Academic Press, 2000:185-202*

References

- ❖ **Lebray P, Zylberberg H, Hue S, Poulet B, Carnot F, Martin S, et al.** Influence of HFE gene polymorphism on the progression and treatment of chronic hepatitis C. *J Viral Hepat* 2004;11:175–182.
- ❖ **Lecube A, Hernandez C, Simo R, Esteban JI, Genesca J.** Glucose abnormalities are an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. *Am J Gastroenterol* 2007;102:2189–2195.
- ❖ **Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, et al.** Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. *Control Clin Trials* 2004;25:472-492.
- ❖ **Levine RA, Sanderson SO, Ploutz-Snyder R, Murray F, Kay E, Hegarty J, et al.** Assessment of fibrosis progression in untreated Irish women with chronic hepatitis C contracted from immunoglobulin anti-D. *Clin Gastroenterol Hepatol* 2006; 4:1271-1277.
- ❖ **Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH.** Pathogenesis, natural history, treatment, and prevention of hepatitis C. *Ann Intern Med* 2000; 132:296-305.
- ❖ **Lieber C.S.:** Hepatitis C and alcohol. *J. Clin. Gastroenterol.* 2003; 36: 100-102.
- ❖ **Lindahl K, Stahle L, Bruchfeld A, Schvarcz R.** High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. *HEPATOLOGY* 2005;41:275-279.
- ❖ **Lindenbach BD, Rice CM:** Unravelling hepatitis C virus replication from genome to function. *Nature* 2005; 436:933–938.
- ❖ **Liu CJ, Chen PJ, Lai MY, Kao JH, Jeng YM, Chen DS.** Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. *Hepatology.* Mar 2003; 37 (3):568-76.
- ❖ **Lohiniva AL, Talaat M, Bodenschatz C, Kandeel A, El-Adawy M, Earhart K, Mahoney FJ.** Therapeutic injections in the context of Egyptian culture. *Promot Educ* 2005;12:13–

References

- ❖ **Lundy SK, Lerman SP & Boros DL.** Soluble egg antigenstimulated T helper lymphocyte apoptosis and evidence for cell death mediated by FasL (+) T and B cells during murine *Schistosoma mansoni* infection. *Infect Immun* 2001; 69: 271–280.
- ❖ **M. Karmochkine, F Carrat, O Dos Santos, and others.** A case-control study of risk factors for hepatitis C infection in patients with unexplained routes of infection. *Journal of Viral Hepatitis* 13(11): 775-782. **November 2006.**
- ❖ **Malaquias LC, Falcao PL, Silveira AM, et al.** Cytokine regulation of human immune response to *Schistosoma mansoni*: analysis of the role of IL-4, IL-5 and IL-10 on peripheral blood mononuclear cell responses. *Scand J Immunol* 1997; 46: 393–398.
- ❖ **Manavi M., Baghestanian M., Watkins-Riedel T., Battistutti W., Pischinger K., Schatten C., Witschko E., Hudelist G., Hofmann H., Czerwenka K.:** Detection of hepatitis C virus (HCV) RNA in normal cervical smears of HCV-seropositive patients. *Clin. Infect. Dis.* 2002; 35: 966-973.
- ❖ **Mangia A, Minerva N, Bacca D, Cozzolongo R, Ricci GL, Carretta V, et al.** Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. *Hepatology* 2008; 47:43–50.
- ❖ **Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al.** Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. *N Engl J Med* 2005; 352:2609-2617.
- ❖ **Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al.** Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet. Sep 22 2001*; 358(9286):958-65.
- ❖ **Mansell CJ, Locarnini SA.** Epidemiology of hepatitis C in the East. *Semin Liver Dis* 1995; 15:15-32.
- ❖ **Marcellin P, Asselah T, Boyer N.** Fibrosis and disease progression in hepatitis C. *Hepatology* 2002; 36:S47-S56.

References

- ❖ **Marcellin P, Martinot M, Boyer N, et al.** Treatment of hepatitis C patients with persistently normal aminotransferase levels. *Clin Liv Dis* 1999; 3:843-853.
- ❖ **Marreoni CA, Younossi ZM, Gramlith T, et al.** Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. *Gastroenterology* 1999;116 :1413-1419
- ❖ **Martín-Carbonero L, Puoti M, García-Samaniego J, et al.** Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4. *J Viral Hepat* 2008; 15: 710–5.
- ❖ **Martinot-Peignoux M, Boyer N, Cazals-Hatem D, Pham BN, Gervais A, Le Breton V, et al.** Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. *HEPATOLOGY* 2001; 34:1000-1005.
- ❖ **Marzano A, Smedile A, Abate M, Ottobrelli A, Brunetto M, Negro F, Farci P, Durazzo M, David E, Lagget M, Verme G, Bonino F, Rizzetto M.** Hepatitis type C after orthotopic liver transplantation: reinfection and disease recurrence. *J. Hepatol.* 1994; 21: 961-965.
- ❖ **Mast EE, Hwang LY, Seto DS, Nolte FS, Nainan OV, Wurtzel H, et al.** Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. *J Infect Dis* 2005; 192:1880-1889.
- ❖ **McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg et al.** Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. *N Engl J Med* 2007;357:2227-2236.
- ❖ **McHutchison JG, Everson GT, Gordon SC, et al.** Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. *N Engl J Med.* Apr 30 2009; 360(18):1827-38.
- ❖ **McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al.** Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. *N Engl J Med.* Nov 19 1998; 339(21):1485-92.

References

- ❖ **McHutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, et al.** The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. *Gastroenterology* 2000; 119:1317–1323.
- ❖ **Meisel H., Reip A., Faltus B., and Lu M., Porst H., Wiese M., Roggendorf M., Krüger D.H.:** Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin. *Lancet* 1995; 345: 1209-1211.
- ❖ **Mele A, Corona R, Tosti ME, Palumbo F, Moiraghi A, Novaco F, et al.** Beauty treatments and risk of parenterally transmitted hepatitis: results from the hepatitis surveillance system in Italy. *Scand J Infect Dis* 1995; 27:441-444.
- ❖ **Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Male PJ, Mentha G, et al.** Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. *J Hepatol* 2000; 33:106–115.
- ❖ **Missiha S, Heathcote J, Arenovich T, Khan K.** Impact of asian race on response to combination therapy with peginterferon alfa- 2a and ribavirin in chronic hepatitis C. *Am J Gastroenterol* 2007;102:2181–2188.
- ❖ **Mohamed MK, Rakha M, Sheir S.** Study of the risk factors for viral hepatitis C infection among Egyptians applying for work abroad . *Egypt Publ Health Ass* 1996; 71:113-47.
- ❖ **Mohamed MK.** Epidemiology of HCV in Egypt 2004. *The Afro-Arab Liver Journal*, 2004, vol 3, No2, (July), pp 41-52).
- ❖ **Mohamed, M. K. et al.** Intrafamilial transmission of hepatitis C in Egypt. *Hepatology*. 42: 683-7. 2000
- ❖ **Montgomery SA, Asberg M.** A new depression scale designed to be sensitive to change. *Br J Psychiatry* 1979; 134:382-389.
- ❖ **Monti G, Galli M, Invernizzi F et al. (1995)** Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC Italian Group for the study of cryoglobulinaemias. *QJ Med* 88, 115–126.

References

- ❖ **Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL.** Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. *Hepatology* 2002; 36:729–736.
- ❖ **Mori M, Hari M, Wada I, et al.** Prospective study of hepatitis B and C viral infections, Cigarette smoking, alcohol consumption and other factors associated with hepatocellular carcinoma risk in Japan. *Am J Epidemiol* 2000;151:131-139?
- ❖ **Moribe T, Hayashi N, Kanazawa Y, Mita E, Fusamoto H, Negi M, et al.** Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy. *Gastroenterology* 1995;108:789–795.
- ❖ **Muir AJ, Bornstein JD, Killenberg PG.** Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. *N Engl J Med* 2004; 350:2265–2271.
- ❖ **Mukherjee S, Rogge J, Weaver L, Schafer DF.** Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation. *Transplant Proc.* Dec 2003; 35(8):3042-4.
- ❖ **Mutimer D, Shaw J, Neuberger J, et al.** Failure to incriminate hepatitis B, hepatitis C, and hepatitis E viruses in the aetiology of fulminant non-A, non-B hepatitis. *Gut* 1995; 36:433–436.
- ❖ **MW Fried, SJ Hadziyannis, M Shiffman, and others.** Rapid virological response is a more important predictor of sustained virological response (SVR) than genotype in patients with chronic hepatitis C virus infection. 43rd annual meeting of the European Association for the Study of the Liver (*EASL 2008*). Milan, Italy. April 23-27, 2008.
- ❖ **Nainan OV, Alter MJ, Kruszon-Moran D, Gao FX, Xia G, McQuillan G, et al.** Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. *Gastroenterology* 2006; 131:478-484.
- ❖ **Narayanan Menon KV, Poterucha JJ, El-Amin OM, Burgart LJ, Kremers WK, et al.** Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. *Liver Transpl.* Jul 2002; 8(7):623-9.

References

- ❖ **National Institutes of Health** Consensus Development Conference Statement: Management of hepatitis C **2002** (June 10-12, 2002). *Gastroenterology*, 2002. 123(6): 2082-99.
- ❖ **Ndjomou J, Pybus OG, Matz B.** Phylogenetic analysis of hepatitis C virus isolates indicates a unique pattern of endemic infection in Cameroon. *J Gen Virol* 2003; 84: 2333–41.
- ❖ **Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al.** Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. *Science* 1998; 282:103–107.
- ❖ **Nguyen MH, Keeffe EB.** Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. *Clin Gastroenterol Hepatol* 2005
- ❖ **Nguyen MH, Trinh HN, Garcia R, Nguyen G, Lam KD, Keeffe EB.** Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin. *Am J Gastroenterol* 2008;103:1131-1135.
- ❖ **Olynyk JK, Reddy KR, Di Bisceglie AM, Jeffers LJ, Parker TI, Radick JL, et al.** Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. *Gastroenterology* 1995;108:1104-1109.
- ❖ **Ortiz V, Berenguer M, Rayon JM, Carrasco D, Berenguer J.** Contribution of obesity to hepatitis C-related fibrosis progression. *Am J Gastroenterol* 2002;97:2408–2414.
- ❖ **Pascu M, Martus P, Hohne M, Wiedenmann B, Hopf U,** patients with chronic hepatitis C virus infection. *J Gastroenterol Hepatol* 2004; 19:314–318.
- ❖ **Patel K, Muir AJ and McHutchison JG** Diagnosis and treatment of chronic hepatitis C infection. *BMJ* 2006;332;1013-1017
- ❖ **Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallee M, et al.** The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. *J Hepatol* 2004; 40:484-490.
- ❖ **Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D.** Standardization of hepatitis C virus RNA quantification. *HEPATOLOGY* 2000;32:654-659.

References

- ❖ **Pawlotsky JM, Lonjon I, Hezode C, Raynard B, Darthuy F, Remire J, et al.** What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories? *HEPATOLOGY* 1998; 27:1700-1702.
- ❖ **Pawlotsky JM.** Molecular diagnosis of viral hepatitis. *Gastroenterology* 2002; 122:1554-1568.
- ❖ **Pearlman BL, Ehleben C, Saifee S.** Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. *HEPATOLOGY* 2007; 46:1688-1694.
- ❖ **Pellicano R, Puglisi G, Ciancio A, Balzola F, Saracco G, Ciccone G, Baldi I, Abate ML, Smedile A and Rizzetto M.** Is serum uric acid a predictive factor of response to IFN-treatment in patients with chronic hepatitis C infection? *J. Med. Virol.* 2008; 80:628-631,
- ❖ **Persico M, Persico E. Suozzo R, et al.** Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. *Gastroenterology* 2000; 118:760-764.
- ❖ **Pessione F, Ramond M, Peters L, et al.** Five-year survival predictive factors in 122 patients with alcoholic cirrhosis:beneficial effects of non-smoking, alcoholic hepatitis and abstinence. *Hepatology*1998;28:384A,
- ❖ **Pessione F, Ramond M-J. Njapouni C, et al.** Cigarette smoking and hepatic lesions in patients with chronic hepatitis C.*Hepatology* 2001;34:121-125
- ❖ **Peters MG and Terrault N.** Alcohol use and hepatitis C. *Hepatology* 2002; 36:S220-S225.
- ❖ **Pietrangelo A.** Iron, oxidative stress and liver fibrogenesis. *J Hepatol* 1998; 28:8–13.
- ❖ **Pilli M, Zerbini A, Penna A, Orlandini A, Lukasiewicz E, Pawlotsky JM, et al.** HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project).*Gastroenterology* 2007;133:1132–1143.
- ❖ **Pockros PJ, Shiffman ML, Schiff ER, Sulkowski MS, Younossi Z, Dieterich DT, et al.** Epoetin alfa improves quality of life in anemic HCVinfected patients receiving combination therapy. *HEPATOLOGY* 2004; 40:1450-1458.
- ❖ **Pontisso P. Gerotto M. Benvegna L, et al.** CO-infection by hepatitis B virus and hepatitis C virus, *Antiviral Ther* 1998; 3:137-142.

References

- ❖ **Poordad F, Reddy KR, Martin P.** Rapid virologic response: a new milestone in the management of chronic hepatitis C. *Clin Infect Dis* 2008; 46: 78–84.
- ❖ **Powell EE, Jonsson JR, Clouston AD.** Steatosis: co-factor in other liver diseases. *HEPATOLOGY* 2005; 42:5-13.
- ❖ **Powell EL, Edwards-Smith CJ, Hay JL, et al.** Host genetic factor influence disease progression in chronic hepatitis. *Hepatology* 2000; 31:828-833.
- ❖ **Poynard T, Bedossa P, Opolon P.** Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. *Lancet* 1997; 349:825-832.
- ❖ **Poynard T, Bedossa P. Metavir and Clinivir Cooperative Study Groups.** Age and platelet count; a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. *J Viral Hepat* 1997; 4:199-208.
- ❖ **Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al.** Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). *Lancet. Oct 31 1998*; 352(9138):1426-32.
- ❖ **Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J.** Is an “a lacarte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. *HEPATOLOGY* 2000;31:211-218
- ❖ **Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al.** Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. *Gastroenterology.* May 2002; 122(5):1303-13.
- ❖ **Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, et al.** Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. *HEPATOLOGY* 2003;38:75-85.

References

- ❖ **Poynard T, Ratziu V, Charlotte F, et al.** Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. *J Hepatol* 2001; 34:730-739.
- ❖ **Pradat P, Tillmann HL, Sauleda S, Braconier JH, Saracco G, Thursz M, et al.** Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. *J Viral Hepat* 2007; 14:556-563.
- ❖ **Puro V, Petrosillo N, Ippolito G.** Risk of hepatitis C seroconversion after occupational exposures in health care workers. Italian Study Group on Occupational Risk of HIV and Other Bloodborne Infections. *AmJ Infect Control* 1995; 23:273-277.
- ❖ **Radloff L.** The CES-D Scale: a self-report depression scale for research in the general population. *J Applied Psychol Measurement* 1977; 1:385-401.
- ❖ **Raison CL, Demetrashvili M, Capuron L, Miller AH.** Neuropsychiatric adverse effects of interferon-alpha: recognition and management. *CNS Drugs* 2005; 19:105-123.
- ❖ **Raison CL, Miller AH.** The neuroimmunology of stress and depression. *Semin Clin Neuropsychiatry* 2001; 6:277-294.
- ❖ **Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL.** Genetic epidemiology of hepatitis C virus throughout *Egypt*. *J Infect Dis* 2000; 182: 698–707.
- ❖ **Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, et al.** Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. *Hepatology* 1999; 30:787–793.
- ❖ **Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pylsopoulos NT, et al.** Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. *AmJ Gastroenterol* 2002; 97:2614-2618.
- ❖ **Reiss G, Keefe EB.** Role of liver biopsy in the management of chronic liver disease: selective rather than routine. *Rev Gastroenterol Disord* 2005; 5:195-205.
- ❖ **Resti M, Jara P, Hierro L, Azzari C, Giacchino R, Zuin G, Zancan L, Pedditzi S, Bortolotti F.** Clinical features and progression of perinatally acquired hepatitis C virus infection. *J. Med. Virol.* 2003; 70: 373-377.

References

- ❖ **Rice P.S., Smith D.B., Simmonds P., Holmes E.:** Heterosexual transmission of hepatitis C virus. *Lancet* 1993; 342: 1052-1053.
- ❖ **Rockey DC, Bissell DM.** Noninvasive measures of liver fibrosis. *HEPATOLOGY* 2006; 43(Suppl):S113-S120.
- ❖ **Rodger Ai, Roberts 5, Lanigan A, et al.** Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971-1975. *Hepatology* 2000; 32:582-587.
- ❖ **Rodriguez-Luna H, Khatib A, Sharma P, De Petris G, Williams JW, Ortiz J, et al.** Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin:an open-label series. *Transplantation.* Jan27 2004; 77(2):190-4.
- ❖ **Rodriguez-Torres M, Jeffers LJ, Sheikh MY, Rossaro L, Ankoma-Sey V, Hamzeh FM, et al.** Virologic responses to Pegifn alpha-2a/ribavirin in treatment-Naive Latino vs non-Latino Caucasians infected with HCV genotype 1: the Latino study. *Gastroenterology* 2008; 134 (Suppl. 1):755A.
- ❖ **Romero-Go´mez M, Ferna´ndez-Rodri´guez CM, Andrade RJ,Diago M, Alonso S, Planas R, et al.** Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. *J Hepatol* 2008;48:721–727.
- ❖ **Romero-Gomez M, Del Mar Vilorio M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, et al.** Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.*Gastroenterology* 2005;128:636-641.
- ❖ **Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB.** Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. *Gastroenterology* 2009; 136: 856–62.
- ❖ **Rubbia-Brandt L, Fabris P, Paganin S, Leandro G, Male PJ, Giostra E, et al.** Steatosis affects chronic hepatitis C progression in a genotype specific way. *Gut* 2004; 53:406-412.

References

- ❖ **Rumi MG, Aghemo A, Prati GM, et al.** Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. **Gastroenterology**. Jan 2010; 138(1):108-15.
- ❖ **Sagir A, Erhardt A, Schmitt M, Haussinger D.** Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. **HEPATOLOGY** 2008; 47:592-595.
- ❖ **Saldanha J, Lelie N, Heath A.** Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. WHO Collaborative Study Group. **Vox Sang** 1999 ; 76:149-158.
- ❖ **Saleh, DA et al.** Incidence and risk factors for hepatitis C infection in a cohort of women in rural Egypt. *Transactions of the Royal Society of Tropical Medicine and Hygiene* (2008)
- ❖ **Salmeron J, Casado J, Rueda PM, Lafuente V, Diago M, Romero-Gomez M, et al.** Quasispecies as predictive factor of rapid, early and sustained virological responses in chronic hepatitis C, genotype 1, treated with peginterferon-ribavirin. **J Clin Virol** 2008; 41:264–269.
- ❖ **Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, et al.** Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. **Gastroenterology**. Mar 2003; 124(3):642-50.
- ❖ **Sanchez-Tapias JM, Diago M, Escartin P, Enriquez J, Romero-Gomez M, Barcena R, et al.** Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. **Gastroenterology** 2006; 131:451-460.
- ❖ **Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al.** Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. **Ultrasound Med Biol** 2003; 29:1705-1713.
- ❖ **Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W, et al.** Interferon signaling and treatment outcome in chronic hepatitis C. *Proc Natl Acad Sci USA* 2008; 105:7034–7039.

References

- ❖ **Sarrazin C, Gartner BC, Sizmann D, Babel R, Mihm U, Hofmann WP, et al.** Comparison of conventional PCR with realtime PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5. *J Clin Microbiol* 2006;44:729–737.
- ❖ **Schaefer M, Engelbrecht MA, Gut O, Fiebich BL, Bauer J, Schmidt F, et al.** Interferon alpha (IFNalpha) and psychiatric syndromes: a review. *Prog Neuropsychopharmacol Biol Psychiatry*. May 2002; 26(4):731-46.
- ❖ **Scheuer PJ.** Classification of chronic viral hepatitis: a need for reassessment. *J Hepatol* 1991; 13:372-374.
- ❖ **Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ.** The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. *N Engl J Med* 1996; 334:1685-1690.
- ❖ **Schreier E, et al.** Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. *Gut* 2004; 53:1345–1351.
- ❖ **Scott JD, Gretch DR.** Molecular diagnostics of hepatitis C virus infection: a systematic review. *Jama* 2007; 297:724-732.
- ❖ **Seef LB, and Hoofnagle JH.** National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C. *Hepatology* 2002; 36 (Suppl 1): S3-S20.
- ❖ **Seeff LB.** The natural history of hepatitis C. *Hepatology* 2002; 36(Suppl):S35-S46.
- ❖ **Sharara AI, Ramia S, Ramlawi F, Fares JE, Klayme S, Naman R.** Genotypes comparison of data with that from other middle Eastern countries. *Epidemiol Infect* 2007;135:427–32.
- ❖ **Shepard CW, Finelli L, Alter MJ:** Global epidemiology of hepatitis C virus infection. *Lancet Infect Dis* 2005; 5:558–567.
- ❖ **Sherif MM, Abou-Aita BAS, Abou-Elew MH, El-Kafrawi A.** Hepatitis B virus infection in upper and lower Egypt. *J Med Virol* 1985;15:129–35.

References

- ❖ **Shiffman ML, Diago M, Tran A, Pockros P, Reindollar R, Prati D, et al.** Chronic hepatitis C in patients with persistently normal alanine transaminase levels. *Clin Gastroenterol Hepatol* **2006**; 4:645-652.
- ❖ **Shiffman ML, Salvatore J, Hubbard S, Price A, Sterling RK, Stravitz RT, et al.** Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. *HEPATOLOGY* **2007**; 46:371-379.
- ❖ **Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, et al.** Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. *N Engl J Med* **2007**; 357:124-134.
- ❖ **Shiha G, Zalata KR.** Does schistosomiasis interfere with application of the Knodell score for assessment of chronic hepatitis C? *Med Sci Monit* **2002**; 8: CR72-77.
- ❖ **Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, et al.** Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. *Gastroenterology* **2004**; 126:840–848.
- ❖ **Shobokshi OA, Serebour FE, Skakni L, Al-Saffy YH, Ahdal MN.** Hepatitis C genotypes and subtypes in Saudi Arabia. *J Med Virol* **1999**; 58: 44–8.
- ❖ **Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, et al.** Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. *HEPATOLOGY* **2005**; 42:962-973.
- ❖ **Simmonds P.** Genetic diversity and evolution of hepatitis C virus – 15 years on. *J Gen Virol* **2004**; 85(Part 11): 3173–88.
- ❖ **Singal AK, Anand BS.** Mechanisms of synergy between alcohol and hepatitis C virus. *J Clin Gastroenterol* **2007**; 41:761–772.
- ❖ **Smnh BC, Grove I, Guzail M, et al.** Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. *Hepatology* **1998**; 27:1695—1699.
- ❖ **Soza A, Everhart JE, Ghany MG, Doo E, Heller T, Promrat K, et al.** Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. *HEPATOLOGY* **2002**; 36:1273-1279.

References

- ❖ **Strader DB, Seeff LB.** *The natural history of chronic hepatitis C infection.* *Eur J Gastroenterol Hepatol* 1996; 8:324-328.
- ❖ **Strader DB, Wright T, Thomas DL, et al.** Diagnosis, management, and treatment of hepatitis C. *Hepatology* 2004;39:1147– 71.
- ❖ **Stramer SL, Caglioti S, Strong DM.** NAT of the United States and Canadian blood supply. *Transfusion* 2000; 40:1165-1168.
- ❖ **Strickland GT, Elhefni H, Salman T, Waked I, Abdel-Hamid M, Mikhail NN, Esmat G, Fix A.** Role of hepatitis C infection in chronic liver disease in Egypt. *Am J Trop Med Hyg* 2002; 67:436–42.
- ❖ **Strickland GT.** Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. *Hepatology* 2006;43:915–22
- ❖ **Stoszek SK, Abdel-Hamid M, Narooz S, et al.** Prevalence of and risk factors for hepatitis C in rural pregnant Egyptian women. *Trans R Soc Trop Med Hyg* 2006; 100: 102–7.
- ❖ **Sulkowski M.S., Ray S.C., Thomas D.L.:** Needlestick transmission of hepatitis C. *J. Amer. Med. Ass.* 2002; 287: 2406-2413.
- ❖ **Sun DX, Zhang FG, Geng YQ, Xi DS.** Hepatitis C transmission by cosmetic tattooing in women. *Lancet* 1996; 347:541.
- ❖ **Talaat M, el-Oun S, Kandeel A, et al.** Overview of injection practices in two governorates in Egypt. *Trop Med Int Health* 2003; 8: 234–41.
- ❖ **Taliani G, Gemignani G, Ferrari C, Aceti A, Bartolozzi D, Blanc PL, et al.** Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. *Gastroenterology* 2006; 130:1098-1106.
- ❖ **Tallis G.F., Ryan G.M., Lambert S.B., Bowden D.S., McCaw R., Birch C.J., Moloney M., Carnie J.A., Locarnini S.A., Rouch G.J., Catton M.G.:** Evidence of patient-to-patient transmission of hepatitis C virus through contaminated intravenous anaesthetic ampoules. *J. Viral Hepat.* 2003; 10: 234-239.
- ❖ **Taylor MW, Tsukahara T, Brodsky L, Schaley J, Sanda C, Stephens MJ, et al.** Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. *J Virol* 2007;81:3391–3401.

References

- ❖ **Terrault NA.** Sexual activity as a risk factor for hepatitis C. *HEPATOLOGY* 2002; 36(Suppl):S99-S105.
- ❖ **Thio CL, Nolt KR, Astemborski J, Vlahov D, Nelson KE, Thomas DL.** Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. *J Clin Microbiol* 2000; 38:575-577.
- ❖ **Thomas DL, Astemnhorski J. Risi RM, et al.** The natural history of hepatitis C virus infection: host, viral and environmental factors. *J Am Med Assoc* 2000; 284:450-456.
- ❖ **Thomas DL, Seeff LB.** Natural history of hepatitis C. *Clin Liver Dis* 2005;9:383-398,
- ❖ **Thorburn B, Curry G. Spooner R, et al.** The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. *Gut* 2002; 50:283-252.
- ❖ **Thorburn D., Roy K., Cameron S.O., Johnston J., Hutchinson S., McCruden E.A.B., Mills P.R., and Goldberg D.J.:** Risk of hepatitis C virus transmission from patients to surgeons: Model based on an unlinked anonymous study of hepatitis C virus prevalence in hospital patients in Glasgow. *Gut* 2003; 52: 1333-1338.
- ❖ **Tong MJ, el-Farra NS, Reikes AR, Co RL.** Clinical outcomes after transfusion-associated hepatitis C. *N Engl J Med* 1995; 332:1463-1466.
- ❖ **Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keeffe EB, et al.** Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. *Hepatology*. Sep 1997; 26(3):747-54.
- ❖ **Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, et al.** Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. *N Engl J Med*. Jul 29 2004; 351(5):438-50.
- ❖ **Tumminelli F, Marcellin P, Rizzo S, Barbera S, Corvino G, Furia P, et al.** Shaving as potential source of hepatitis C virus infection. *Lancet* 1995; 345:658.

References

- ❖ **Uemura K, Kawaguchi T, Sodeyama T, et al.** Antibody to hepatitis C virus in-patients with chronic schistosomiasis. *Ann Trop Med Parasitol* 1992; 86:257-62.
- ❖ **Utsumi T., Hashimoto E., Okumura Y., Takayanagi M., Nishikawa H., Kigawa M., Kumakura N., Toyokawa H.:** Heterosexual activity as a risk factor for the transmission of hepatitis C virus. *J. Med. Virol.* 1995; 46: 122-125.
- ❖ **Van der Kleij D, Latz E, Brouwers JF, et al.** A novel host-parasite lipid cross-talk. Schistosomal lyso-phosphatidylserine activates toll-like receptor 2 and affects immune polarization. *J Biol Chem* 2002; 277: 48122–48129.
- ❖ **Van Thiel DH, Faruki H, Friedlander L, Fagiuoli S, Caraceni P, Molloy PJ, et al.** Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. *Hepatogastroenterology.* Nov-Dec 1995; 42(6):907-12.
- ❖ **Van Thiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavalier JS.** Response to interferon alpha therapy is influenced by the iron content of the liver. *J Hepatol* 1994; 20:410–415.
- ❖ **Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al.** Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. *Ann Intern Med* 2007;147:677-684. HEPATOLOGY, Vol. 49, No. 4, 2009 GHANY ET AL. 1367
- ❖ **Villa E, Grottola A, Buttafoco P, Colantoni A, Bagni A, Ferretti I, et al.** High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. *Am J Gastroenterol.* Oct 2001; 96(10):2973-7.
- ❖ **Vogt M, Lang T, Frosner G, Klingler C, Sendl AF, Zeller A, et al.** Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. *N Engl J Med* 1999; 341:866-870.

References

- ❖ **Vi.Wong JB, Koff RS.** Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C.A cost-effectiveness analysis. *Ann Intern Med* 2000;133:665-675
- ❖ **von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al.** Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. *Gastroenterology* 2005;129:522-527.
- ❖ **Wasley A, Miller JT, Finelli L.** Surveillance for acute viral hepatitis —United States, 2005. *MMWR Surveill Summ* 2007;56:1-24.
- ❖ **Westin J, Lagging M, Dhillon AP, Norkrans G, Romero AI, Pawlotsky JM, et al.** Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. *J ViralHepat* 2007; 14:29-35.
- ❖ **Wiese M, Berr F, Lafrenz M, Porst H, Oesen U.** Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. *HEPATOLOGY* 2000; 32:91-96.
- ❖ **Wiese M, Grungreiff K, Guthoff W, Lafrenz M, Oesen U, Porst H.** Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany a 25-year multicenter study. *J Hepatol* 2005; 43:590-598.
- ❖ **Wiese M, Bert F, Lafrenz M, et al.** Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20 year multicenter study. *Hepatology* 2000; 32:91-96.
- ❖ **Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ.** Impact of alcohol on the histological and clinical progression of hepatitis C Infection. *Hepatology. Sep* 1998; 28(3):805-9.
- ❖ **Wiley TE, Brown J, Chan J.** Hepatitis C virus infection in African Americans its natural history and histological progression. *Am J Gastroenterol* 2002; 97:700-706?
- ❖ **Williams R.** Global challenges in liver disease. *HEPATOLOGY* 2006; 44:521-526.
- ❖ **Workowski KA, Berman SM.** Sexually transmitted diseases treatment guidelines, 2006. *MMWR Recomm Rep* 2006; 55:1-94.

References

- ❖ **World Health Organization.** Hepatitis C. WHO fact sheet164. Availableat<http://www.who.int/mediacentre/factSheets/fs164/en/print.html> (**accessed 21 January 2009**).
- ❖ **Wright T.L., Donegan E., Hsu H.H., Ferrell L., Lake J.R., Kim M., Combs C., Fennessy S., Roberts J.P., Ascher N.L., Greenberg H.B.:** Recurrent and acquired hepatitis C viral infection in liver transplant recipients. *Gastroenterology* 1992; 103: 317-322.
- ❖ **World Health Organization.** Hepatitis C. www.who.int/immunization/topics/hepatitis_c/en/.
- ❖ (www.hcvadvocate.org.), a series of fact sheets written by experts in the field of liverdisease: Hepatitis C Support Project • a nonprofit organization for HCV education, support and advocacy• © 2008 Hepatitis C
- ❖ **Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, et al.**The long-term pathological evolution of chronic hepatitis C. *HEPATOLOGY* 1996;23:1334-1340.
- ❖ **Yu JW, Wang GQ, Sun LJ, Li XG, Li SC.** Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. *J Gastroenterol Hepatol* 2007; 22:832-836.
- ❖ **Yu ML, Dai CY, Huang JF, Hou NJ, Lee LP, Hsieh MY, et al.** A randomized study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. *Gut* 2007; 56:553-559.
- ❖ **Yu ML, Dai CY, Lee LP, Hou NJ, Hsieh MY, Huang JF, et al.** A 24-week course of high-dose interferon-alpha plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels. *Liver Int* 2006; 26:1187-1195.
- ❖ **Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, et al.**Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitisCand normal aminotransferase levels. *Gastroenterology*2004; 127:1724-1732.
- ❖ **Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al.** Peginterferon alfa-2a in patients with chronic hepatitis C. *N Engl J Med.* Dec 7 2000 ;343(23):1666-72.

References

- ❖ **Zeuzem S, Fried MW, Reddy KR, Marcellin P, Diago M, Craxi A, et al.** Improving the clinical relevance of pretreatment viral load as a predictor of sustained virological response (SVR) in patients infected with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) (PEGASYS (R)) plus ribavirin(COPEGUS (R)). *Hepatology* 2006; 44 (Suppl. 1):267A–268A.
- ❖ **Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M, et al.** Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha 2a. *Gastroenterology* 2001; 120:1438–1447.
- ❖ **Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al.** Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. *J Hepatol* 2004; 40:993–999.
- ❖ **Zeuzem S, Schmidt JM, Lee JH, Ruster B, Roth WK.** Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. *Hepatology* 1996; 23:366–371.
- ❖ **Zeuzem S, Welsch C, Herrmann E.** Pharmacokinetics of peginterferons. *Semin Liver Dis* 2003; 23(Suppl 1):23-28.
- ❖ **Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al.** Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. *J Hepatol* 2006; 44:97–103.
- ❖ **Zignego AL, Brechot C (1999)** Extrahepatic manifestations of HCV infection: facts and controversies. *J Hepatol* 31, 369–376.
- ❖ **Zignego A.L., Ferri, C., Pileri, S.A., Caini, P., Bianchi, F.B., 2007a.** Extrahepatic manifestations of Hepatitis C virus infection: a general overview and guidelines for a clinical approach. *Dig. Liver Dis.* 39, 2–17.
- ❖ **Zuckerman J., Clewley G., Griffiths P., Cockcroft A.:** Prevalence of hepatitis C antibodies in clinical health-care workers. *Lancet* 1994; 343: 1618-1620.
- ❖ **Zung WW.** A Self-Rating Depression Scale. *Arch Gen Psychiatry* 1965; 12:63-70.